Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™

Bioprocessing

Bioprocessing and Capacity Trends: Growth Despite Continued Uncertainty

Cynthia A. Challener, Ph.D.

Pharma's Almanac

DS + DP Integration

Integrating Drug Substance and Drug Product to Reduce Risk Across Development

Dörthe Ackenhausen

IDT Biologika

Multi-Modality CDMO

The Rise of the Multi-Modality CDMO: Why Clients Need More Than Capacity

Kamal Preet

OneSource Specialty Pharma

DSP

Why More Product Upstream Creates New Pressure Downstream

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac

Biosimilars

The Global Division of Labor Behind the Coming Oncology Biosimilar Wave

Pharma's Almanac

Single-Use

The Changing Economics of Single-Use Biomanufacturing

Pharma's Almanac

Biologics Platform

Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities

Mathias Kahl

IDT Biologika